ENXTPA:DIMLife Sciences
Sartorius Stedim Biotech (ENXTPA:DIM) Margin Gain Reinforces Bullish Earnings Narrative
Sartorius Stedim Biotech (ENXTPA:DIM) has put fresh numbers on the table for FY 2025, with fourth quarter revenue of €772.2 million and basic EPS of €0.49, alongside trailing twelve month EPS of €2.73 and total revenue of €2.97 billion setting the backdrop for the year. The company has seen quarterly revenue move from €655.4 million in Q3 2024 to €772.2 million in Q4 2025, while basic EPS has shifted from €0.26 to €0.49 over the same span. This gives investors a clear view of how top line and...